Terapêutica anticoagulante e dupla anti-agregação plaquetar combinadas, um desafio à inteligência

Andreotti, 2006, Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25. 307 patients, Eur Heart J, 27, 519, 10.1093/eurheartj/ehi485 2011, Eur Heart J, 32, 2999, 10.1093/eurheartj/ehr236 2010, Eur Heart J, 31, 2501, 10.1093/eurheartj/ehq277 Mehta, 2003, Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation, Am J Cardiol, 92, 1031, 10.1016/j.amjcard.2003.06.001 2006, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet, 367, 1903, 10.1016/S0140-6736(06)68845-4 Dewilde, 2009, Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST), Am Heart J, 158, 713, 10.1016/j.ahj.2009.09.001 Schömig, 1996, A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents, N Engl J Med, 334, 1084, 10.1056/NEJM199604253341702 Leon, 1998, A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting, N Engl J Med, 339, 1665, 10.1056/NEJM199812033392303 Bertrand, 1998, Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) Study, Circulation, 98, 1597, 10.1161/01.CIR.98.16.1597 Urban, 1998, Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in highrisk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS), Circulation, 98, 2126, 10.1161/01.CIR.98.20.2126 Rubboli, 2005, Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting, Cardiology, 104, 101, 10.1159/000086918 Nguyen, 2007, Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?, Eur Heart J, 28, 1717, 10.1093/eurheartj/ehm186 Gilard, 2009, Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral anticoagulants [STENTICO]), Am J Cardiol, 104, 338, 10.1016/j.amjcard.2009.03.053 Zhao, 2011, Triple therapy” rather than “triple threat”: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment, Chest, 139, 260, 10.1378/chest.09-3083 Marques da Silva P. Velhos e novos anticoagulantes orais. Perspetiva farmacológica. Rev Port Cardiol. 2012.(in press). Huo, 2011, New oral anticogulants in venous thromboembolism prophylaxis in orthopaedic patients: are they really better?, Thromb Haemost, 106, 45, 10.1160/TH10-10-0653 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Oldgren, 2011, Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial, Eur Heart J, 32, 2781, 10.1093/eurheartj/ehr113 Steg, 2011, RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome, Eur Heart J, 32, 2541, 10.1093/eurheartj/ehr334 Alexander, 2009, Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, Circulation, 119, 2877, 10.1161/CIRCULATIONAHA.108.832139 Mega, 2009, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial, Lancet, 374, 29, 10.1016/S0140-6736(09)60738-8 Alexander, 2011, Apixaban with antiplatelet therapy after acute coronary syndrome, New Engl J Med, 365, 699, 10.1056/NEJMoa1105819 Mega, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277 Lip, 2010, Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting, Thromb Haemost, 103, 13, 10.1160/TH09-08-0580 Faxon, 2011, Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North-American perspective, Thromb Haemost, 106, 572 Huber, 2011, Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe, Thromb Haemost, 106, 569, 10.1160/TH11-08-0602